SCHEDULE: Deep Track Capital Boosts Stake in LB Pharmaceuticals

Deep Track Capital and its affiliates have increased their beneficial ownership in LB Pharmaceuticals Inc to 11.7% following a private placement of common stock and pre-funded warrants.

Summary

• Deep Track Capital and its affiliates, including Deep Track Biotechnology Master Fund, Ltd. and Deep Track Special Opportunities Fund, LP, have increased their beneficial ownership in LB Pharmaceuticals Inc.
• The increase stems from a private placement that closed on February 6, 2026, where LB Pharmaceuticals issued 3,306,571 shares of Common Stock and pre-funded warrants for up to 1,417,107 shares.
• Each share was sold at $21.17, and each pre-funded warrant at $21.1699, with an exercise price of $0.0001.
• Deep Track Biotechnology Master Fund, Ltd. purchased 378,444 pre-funded warrants, and Deep Track Special Opportunities Fund, LP purchased 93,925 pre-funded warrants.
• The reporting persons' beneficial ownership is subject to a 9.99% maximum percentage limitation, meaning the pre-funded warrants are not currently exercisable to avoid exceeding this threshold.
• LB Pharmaceuticals Inc. has agreed to file a Form S-1 registration statement within 60 days of the closing date (by April 7, 2026) to register the resale of the newly issued shares and warrant shares.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as a significant institutional investor has increased its stake, providing capital to the company. The ownership limitation on warrants introduces a minor complexity for the investor.

Positives

• Significant investment by institutional funds (Deep Track Capital) indicates confidence in LB Pharmaceuticals Inc.
• The private placement provides capital to LB Pharmaceuticals Inc.
• The registration rights agreement ensures liquidity for the investors' shares in the future.

Negatives

• The 9.99% ownership limitation on the pre-funded warrants restricts immediate full exercise by the reporting persons, potentially limiting their upside or influence.

Risks

• The inability to immediately exercise pre-funded warrants due to the 9.99% beneficial ownership limitation could impact the reporting persons' investment strategy or potential returns.
• Failure by the Issuer to timely file or achieve effectiveness of the S-1 registration statement could delay liquidity for the investors.

Future Outlook

LB Pharmaceuticals Inc. is obligated to file a Form S-1 registration statement within 60 days of the private placement closing (by April 7, 2026) to register the resale of the newly issued shares and warrant shares. The company will use reasonable best efforts to have this registration statement declared effective within 90 days of its initial filing and maintain its effectiveness until the shares are sold or can be resold without restriction under Rule 144.

Industry Context

StockSavvy.ai notes that private placements are a common method for biotechnology companies like LB Pharmaceuticals Inc. to raise capital, especially for funding research and development or clinical trials. The involvement of specialized funds like Deep Track Capital, which focuses on biotechnology, suggests a targeted investment in the sector. The registration rights agreement is standard practice to provide liquidity for institutional investors in such private transactions.

Stakeholder Impact

• Shareholders: Existing shareholders experience dilution from the issuance of new shares and potential future dilution from warrant exercise, but the capital raise could support company growth. The increased institutional ownership might be seen as a positive signal.
• Company (LB Pharmaceuticals Inc.): Receives capital from the private placement to fund operations or strategic initiatives.
• Investors (Deep Track Capital affiliates): Increase their stake in LB Pharmaceuticals Inc. and gain registration rights for future liquidity, though immediate warrant exercise is limited.

Next Steps

• LB Pharmaceuticals Inc. to file a Form S-1 registration statement within 60 days of February 6, 2026 (by April 7, 2026).
• LB Pharmaceuticals Inc. to use reasonable best efforts to have the S-1 registration statement declared effective within 90 days of its initial filing.
• LB Pharmaceuticals Inc. to maintain the effectiveness of the registration statement until the shares are sold or can be resold under Rule 144 without restriction.

Key Dates

Recommendation

The increased institutional ownership by Deep Track Capital, coupled with the capital raise, suggests a vote of confidence in LB Pharmaceuticals Inc. and provides the company with additional funding. However, the dilution from the new share issuance and the limitations on warrant exercise for the reporting persons introduce complexities. Without further operational or financial performance details, a 'hold' recommendation is appropriate, awaiting more comprehensive insights into how the raised capital will be deployed and its impact on future growth.

Keywords

LB Pharmaceuticals, Deep Track Capital, Private Placement, Schedule 13D, Common Stock, Pre-Funded Warrants, Biotechnology, Investment, SEC Filing, Shareholder Ownership